The FDA has approved Juluca®, the first two-drug regimen for maintenance treatment of HIV infection in adults, with the hope of presenting additional treatment options and lessening the burden on HIV-infected adults.
Browsing: Viral > HIV / AIDS
Scientists have explored how the viral genome affects the infectious potency of HIV; discovering that viruses have likely evolved to remove CG dinucleotides in order to avoid surveillance to mammalian defence mechanisms.
Results from the Positive Perspectives global survey have been reported at the recent EACS conference, providing insights into the attitudes of HIV patients towards treatment, healthcare and stigma.
Despite significant advances in the treatment of human immunodeficiency virus (HIV), there remain challenges. This review highlights recent advances in the application of nanotechnology to drug delivery, specifically with the purpose of improving HIV therapy.
Researchers have developed a novel compound, L-HIPPO, which can prevent viral budding in HIV-infected cells. It has been suggested this compound could supplement existing ‘kick and kill’ strategies, allowing complete eradication of HIV in the body.
A novel trispecific antibody has been developed by researchers from the NIH and Sanofi, demonstrating effectiveness against of 99% of HIV strains and protective immunity in non-human primates.
Researchers have identified the mTOR pathway as a ‘druggable’ key regulator of HIV-1 persister reservoirs in gut-homing CD4+ T cells.
Data from Population-based HIV Impact Assessments in five African countries have demonstrated promising progress towards controlling the HIV epidemic by 2020, however, they have also highlighted gaps.
Evidence has emerged suggesting a link between certain hormonal contraceptives and HIV acquisition risk. This article reviews the epidemiologic studies and potential biologic mechanisms evaluating the association between hormonal contraceptive methods and HIV risk.
Researchers have identified a new treatment approach for acute HIV-infected patients, which targets human proteins rather than the virus.